A phase 1 clinical trial of ASG-5ME, a novel drug-antibody conjugate targeting SLC44A4, in patients with advanced pancreatic and gastric cancers
Coveler, Andrew L., Ko, Andrew H., Catenacci, Daniel V. T., Von Hoff, Daniel, Becerra, Carlos, Whiting, Nancy C., Yang, Jing, Wolpin, BrianVolume:
34
Language:
english
Journal:
Investigational New Drugs
DOI:
10.1007/s10637-016-0343-x
Date:
June, 2016
File:
PDF, 342 KB
english, 2016